The results of an Israeli study published in the prestigious international journal Nature Breast Cancer show that chemotherapy can be avoided in women with breast cancer, discovered in the beginning.
According to a report by Yediot Aharonot, researchers have followed, for a decade, 1365 women in Israel who have the two most common cancers (ER positive and HER2 negative).
As part of the study, women underwent an oncotype test, during which they were each rated on a scale from 0 to 100 in terms of the risk of cancer recurrence. Each patient with a score of 25 or less was advised to discontinue chemotherapy. In almost 100 percent of women, the disease did not recur, although they did not receive chemotherapy.
The Journal explains that the breast oncotype is a unique molecular test made on tumor tissue taken from a patient at the time of biopsy or at the time of initial surgery. The test measures the biological profile of the tumor by measuring the expression of 21
The study results show that among 97.4% of women who gave up chemotherapy after the test, the disease did not recur. The mortality rate in the patient group was only 0.7%.
This is great news since chemotherapy often has serious health effects over the years. One of the high risks it poses is serious damage to the immune system, which can be life-threatening.
The study was conducted by senior oncologists, including Dr. Shulamit Riesel of Asuta Hospital, Dr. Noah Ben Baruch of Kaplan Hospital, and Dr. Lior Shoshan-Gutman, CEO of Oncotest.
Professor Solomon Statter, director of the research department at the Bylinson Cancer Institute and among researchers, said in Yediot Aharonot that "research proves beyond doubt that chemotherapy can be denied to most women who have cancer breast detected early. "